

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/595,947	06/16/2000	Christine Icard-Liepkalns	2918	
5487	7590 06/21/2005		EXAMINER	
ROSS J. OEHLER			KAM, CHIH MIN	
AVENTIS P ROUTE 202	HARMACEUTICALS INC206		ART UNIT	PAPER NUMBER
MAIL CODE: D303A		1653		
BRIDGEWATER, NJ 08807			DATE MAILED: 06/21/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Supplemental						
Notice	of Allowabi	lity				

Application No.	Applicant(s)	
09/595,947	ICARD-LIEPKALNS ET AL.	
Examiner	Art Unit	
Chih-Min Kam	1653	

·			
	Chih-Min Kam	1653	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not include will be mailed in due	ed course, THIS
1. This communication is responsive to 4/20/05.			
2. The allowed claim(s) is/are 6,8,9,21,22,24,26-30,40 and 42	<u>2-46</u> .		
3. \boxtimes The drawings filed on <u>16 June 2000</u> are accepted by the E	xaminer.		
 4. Acknowledgment is made of a claim for foreign priority unal All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	been received. been received in Application No. <u>09</u>		tion from the
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a reply of this application.	complying with the rec	quirements
5. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINER' es reason(s) why the oath or declarate	S AMENDMENT or N tion is deficient.	OTICE OF
6. CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.		
(a) ☐ including changes required by the Notice of Draftspers		948) attached	
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		•	4
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in t	84(c)) should be written on the drawin he header according to 37 CFR 1.121(d	gs in the front (not the i).	back) of
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT I	sit of BIOLOGICAL MATERIAL m FOR THE DEPOSIT OF BIOLOGICA	nust be submitted. N AL MATERIAL.	lote the
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informal Pa	• • • • •)-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary (Paper No./Mail Date		
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	8), 7. 🛛 Examiner's Amendm		
4. Examiner's Comment Regarding Requirement for Deposit	8. Examiner's Stateme	nt of Reasons for Allo	wance
of Biological Material	9.		

Application/Control Number: 09/595,947

Art Unit: 1653

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jonathan Dermott on June 15, 2005.

Examiner's Amendments to the Claims:

Claims 6 and 9 have been amended as follows:

- 6. (Currently amended) An isolated nucleic acid comprising a polynucleotide sequence as depicted in SEQ ID NO: 1, or a the complementary polynucleotide sequence of said isolated nucleic acid.
- 9. (Currently amended) A nucleotide probe specific for a neurogenin 3 (ngn3) nucleic acid, wherein the nucleotide probe comprises a the complementary polynucleotide sequence of SEQ ID NO: 1.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/595,947

Art Unit: 1653

Page 3

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D.

Patent Examiner

CMK

June 15, 2005

JON WEBER SUPERVISORY PATENT EXAMINER